National Cell Respository for Alzheimer's Disease (NCRAD) (U24)

描述(由申请人提供)：国家阿尔茨海默病细胞库(NCRAD)在国家老龄研究所(NIA)识别阿尔茨海默病(AD)高危人群并开发改进的治疗方法以延迟或预防疾病发病的努力中发挥着关键作用。NCRAD是与NIA达成的合作协议，作为NIA资助的所有痴呆症研究的主要样本共享来源。在NIA和细胞库咨询委员会的建议下，NCRAD的使命是消除阻碍研究进展的关键障碍，以了解痴呆症的病因。为了实现这一目标，NCRAD有两个主要职能：样本银行和样本分发。NCRAD作为一个中央储存库，使用统一的协议和广泛的质量措施保存来自NIA资助的正在进行的研究的样本。储存的样本类型已经扩大到包括DNA、细胞系、血浆、血清、脑组织和RNA。NCRAD与国家阿尔茨海默病协调中心(NACC)密切合作，NACC是NIA的另一个核心机构，作为所有阿尔茨海默病中心(ADC)的数据协调中心。NCRAD和NACC共同充当阿尔茨海默病遗传学联合会(ADGC)的关键资源，协调从29个ADDC收集样本。NCRAD还广泛地将样本分发给研究人员进行自己的分析以及中央核心，在中央核心进行APOE基因分型、全基因组SNP阵列，现在进行全基因组和全外显子组测序研究。我们建议扩大我们的成功努力，实现以下具体目标：1.为所有NIA资助的痴呆症研究提供最先进的中央生物标本库，其中包括为DNA、细胞系、血浆、血清、RNA和脑组织的安全银行提供详细的标准操作程序。2.向所有有资格的调查人员分发数据和生物检验品，以便在其研究中使用，从而促进和促进样本共享。 公共卫生相关性：有许多障碍阻碍了研究人员对阿尔茨海默病和相关痴呆进行成功研究的能力。其中包括共享样本的能力、获取大量高质量样本的能力以及有效分享研究成果的能力。在NIA和CBAC的建议下，NCRAD将解除这些禁令，并促进痴呆症研究人员之间的样本和数据共享。

DESCRIPTION (provided by applicant): The National Cell Repository for Alzheimer's Disease (NCRAD) plays a key role in the National Institute on Aging's (NIA) efforts to identify those at risk for Alzheimer disease (AD) and develop improved treatments to delay or prevent disease onset NCRAD was established as a cooperative agreement with the NIA to serve as the primary source of sample sharing for all NIA-funded dementia studies. Under the advisement of NIA and the Cell Bank Advisory Committee, it is the mission of NCRAD to remove critical barriers hindering research progress to understand the etiology of dementia. To achieve this goal, NCRAD has two primary functions: sample banking and sample distribution. NCRAD serves as a central repository banking samples from ongoing NIA funded studies using uniform protocols with extensive quality measures. The type of samples being banked has expanded to include DNA, cell lines, plasma, serum, brain tissue and RNA. NCRAD works closely with the National Alzheimer Coordinating Center (NACC), another NIA core facility that serves as the data coordinating center for all the Alzheimer Disease Centers (ADCs). Together, NCRAD and NACC serve as key resources within the Alzheimer Disease Genetics Consortium (ADGC), coordinating the collection of samples from the 29 ADCs. NCRAD also widely distributes samples both to investigators for their own analyses as well as to central cores, where APOE genotyping, genome wide SNP arrays, and now whole genome and whole exome sequencing studies are performed. We propose to expand our successful efforts with the following specific aims; 1. To provide a state-of-the-art central bio specimen repository for all NIA-funded dementia studies that includes detailed standard operating procedures for the secure banking of DNA, cell lines, plasma, serum, RNA, and brain tissue. 2. To facilitate and foster sample sharing by distributing data and biospecimens to all qualified investigators for use in their research studies. PUBLIC HEALTH RELEVANCE: There are a number of barriers that hamper the ability of researchers to perform successful studies of Alzheimer disease and related dementias. These include the ability to share samples, access to large numbers of high quality samples and effective sharing of research results. NCRAD under the advisement of NIA and CBAC will lift these ban-iers and facilitate sample and data sharing among dementia researchers.